Dyne Therapeutics, Inc. (DYN)
Nasdaq: DYN · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2020
Who owns Dyne Therapeutics, Inc.
As filed with the SECHolders of 5% or more
4
T. Rowe Price Investment Management, Inc. holds 18.7% of COMMON STOCK, as its SCHEDULE 13G/A filed May 15, 2026 says.
Directors and officers
13
report now, of 21 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
T. Rowe Price Investment Management, Inc.
SCHEDULE 13G/A · filed May 15, 2026 · COMMON STOCK · 16.2% in Mar 6, 2026
JANUS HENDERSON GROUP Ltd.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · 8.3% in May 15, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 28, 2026 · Common Stock · 5.8% in Apr 17, 2025
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 5.4% in May 6, 2026
ForDyne B.V.
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.0001 · reported falling below 5%
Atlas Venture Fund XI, L.P.
SCHEDULE 13G/A · filed Aug 13, 2026 · COMMON STOCK, $0.0001 PAR VALUE · reported falling below 5%, from 4% in Nov 13, 2025
RTW Investments, LP
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.1% in Feb 14, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.1% in Feb 3, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 8.5% in May 15, 2025
What DYN reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 27, 2025.
Insider tradesForm 4
122sales
8purchases
121sales on a scheduled plan
6people selling
$169Msold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Oct 22, 2025 to Oct 22, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 22, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 41 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Rhodes Jason P | director | 79 | $129M | 79 | 0 | $0 |
| Kersten Dirk | director | 19 | $38.6M | 19 | 0 | $0 |
| Cox John | CEO & President | 6 | $400,000 | 6 | 0 | $0 |
| Lucera Erick | Chief Financial Officer | 4 | $200,000 | 3 | 0 | $0 |
| Kerr Douglas | Head of R&D and CMO | 7 | $200,000 | 7 | 0 | $0 |
| Posner Brian S | director | 0 | $0 | 0 | 8 | $300,000 |
| Friedl-Naderer Johanna | Chief Commercial Officer | 7 | $0 | 7 | 0 | $0 |